Slide 1: Revolutionizing Medicines and Materials Discovery
Revolutionizing Medicines and Materials Discovery 1Q25 Financial Results May 7, 2025
Slide 2: Cautionary Note and Disclaimer
Cautionary Note and Disclaimer This presentation contains certain "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical fact, made by Schröding
Slide 3: Digital Chemistry Laboratory Leverages Physics + AI
Digital Chemistry Laboratory Leverages Physics + AI Physics + AI Physics-based Training Set for AI/ML Artificial Intelligence / Methods Generated Using Physics Machine Learning ✓ No training set required ✓ Fast ✓ Effective at interpolation ✓ Can extrapolate into novel ✓ Accurate ✓ Fast chemical spac
Slide 4: Multi-Pronged Business Enabled by Highly Differentiated Computational Platform
Multi-Pronged Business Enabled by Highly Differentiated Computational Platform SOFTWARE LICENSING • Life Sciences COLLABORATIONS • Materials Design • Drug Design PROPRIETARY PIPELINE ~1,752 customers worldwide1 • Materials Design 19 drug discovery collaborators2 • Drug Discovery & Development 8+ act
Slide 5: Highlights
Highlights 1Q25 Financial Results Phase 1 Data Readouts on 2025 Guidance Highlights • $59.6M total revenue Track • 10% - 15% software growth • $48.8M software revenue • SGR-1505 June 2025 • $45M - $50M drug discovery • $10.7M drug discovery – EHA: June 12 - 15 revenue revenue – ICML: June 17 - 21 •
Slide 6: Advancing the Platform in 2025
Advancing the Platform in 2025 Continuing to Integrate Physics & AI/ML Target Hit Lead Preclinical Validation Discovery Optimization Development High Resolution Protein Biologics Informatics Formulation & Crystal Structure Prediction Structure Prediction AI/ML Integration in Informatics Platform Vir
Slide 7: A Broad Portfolio of Advancing Collaboration Programs
A Broad Portfolio of Advancing Collaboration Programs(1)(2) Phase 1 Phase 2 Phase 3 FDA-Approved TIBSOVO4 Immuno-oncology Metabolic Diseases3 Psoriasis3 IDHIFA4 Myelofibrosis Inflammatory Bowel Disease5 Undisclosed Undisclosed Obesity Undisclosed Undisclosed Additional programs in discovery and prec
Slide 8: Proprietary Pipeline Approaching Key Clinical Milestones
Proprietary Pipeline Approaching Key Clinical Milestones DISCOVERY PRECLINICAL PHASE 1 SGR-1505 (MALT1) R/R B-cell Malignancies* SGR-2921 (CDC7) R/R AML/MDS* SGR-3515 (Wee1/Myt1) Solid Tumors SGR-4174 (SOS1) Solid Tumors EGFRC797S Solid Tumors NLRP3 Immunology LRRK2 Neurology Undisclosed Programs Mu
Slide 9: Clinical Programs with Breakthrough Potential
Clinical Programs with Breakthrough Potential SGR-1505 SGR-2921 SGR-3515 (MALT1) (CDC7) (Wee1/Myt1) • Generally well tolerated in • Potent and selective CDC7 • Clinically validated target healthy volunteers inhibition shows strong • Potential benefit in wide range anti-proliferative activity in AML
Slide 10: 1Q25 Financial Highlights vs. 1Q24
1Q25 Financial Highlights vs. 1Q24 Three Months Ended March 31 1Q 2024 1Q 2025 % Change Software revenue $33.4 $48.8 46% Drug discovery revenue $3.2 $10.7 237% Total revenue $36.6 $59.6 63% Gross profit $18.9 $31.1 Software gross margin 76% 72% Operating expenses $86.3 $82.0 (5.0%) Other (expense)/i
Slide 11: Four-Quarter Trailing Average Software Quarterly Revenue Trend
Four-Quarter Trailing Average Software Quarterly Revenue Trend 50 48.9 45.1 42.3 39.8 40.1 41.6 40 33.9 33.7 33.5 34.6 30.0 31.5 31.6 30 28.3 $ Millions 23.8 24.6 24.9 23.1 21.3 19.6 20 18.0 10 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 2020 2020 2020 2020 2021 2021 2021 2021 2
Slide 12: Hosted Contracts Are a Growing Share of Total Software Revenue
Hosted Contracts Are a Growing Share of Total Software Revenue Hosted Contracts as % of Software Revenue (Trailing Hosted Contract Revenue 4-Quarter Average, %) 100% Hosted Software Share of Software Revenue ($M) 75% Revenue (%) 50% 25% 0% 2020 2021 2022 2023 2024 2025 2020 2021 2022 2023 2024 2025
Slide 13: 2025 Financial Guidance
2025 Financial Guidance (As of May 7, 2025) 2024 Actual 2025 Guidance Software revenue $180.4 +10% – 15% Drug discovery revenue $27.2 $45 – $50 Software gross margin 80% 74% – 75% Operating expense growth 7.3% Less than 5% Cash used in operating activities $157.4 Lower than 2024 (in millions) For th
Slide 14: Strategic Priorities
Strategic Priorities • Increase customer adoption of computational technology • Deliver planned major enhancements to the platform • Present initial clinical data from the Phase 1 study of SGR-1505 in June 2025 • Present initial clinical data from the Phase 1 study of SGR-2921 in 2H 2025 • Present i
Slide 15: Revolutionizing Medicines and Materials Discovery
Revolutionizing Medicines and Materials Discovery May 2025
Slide 16: Appendix
Appendix Annual Contract Value (ACV). With respect to contracts that have a duration of one year or less, or contracts of more than one year in duration that are billed annually, ACV is defined as the contract value billed during the applicable period. For contracts with a duration of more than one